ALTHX — Thx Pharma SA Share News
0.000.00%
Last trade - 00:00Brief: Theranexus Announces Inclusion Of First Patient In Phase 2 Clinical Trial For THN102
Brief: Theranexus To Present New Data On Medicine Candidate Thn102
Brief: Theranexus Announces German Authorities Approval For Its Phase 2 Clinical Trial In Parkinson's Disease
Brief: Theranexus Publishes Scientific Article On Mechanism Of Action Of Drug Candidate THN102
Brief: Theranexus Cash And Cash Equivalents At 31 March 2018 At 16,172,000 Euros
Brief: Theranexus FY Net Loss Widens To 2.1 Million Euros
Brief: Theranexus Announces First European Authorization For Clinical Study Of Phase 2 With Thn 102 In Parkinson's Disease
Brief: Theranexus Announces Successful Study In Development Of THN201 And THN101
Brief: Theranexus And College De France Sign Research Agreement On Astrocyte-Neuron Interactions
Brief: Theranexus Announces Issuance Of European Patent Covering Its Drug Candidate THN102 For Treatment Of Narcolepsy and Parkinson's Disease
Brief: Theranexus Announces New Ipo Value At 20.4 Million Euros